Long-term (5 years) efficacy and safety of infliximab in Crohn´s disease patients
19th UEGW
Stockolm 22-26
October 2011Gut 2011; 60 (Suppl III): A-192
Investigación
New Genetic Associations Detected in an Exome-Wide Association Study for Toxicity Related to Thiopurine Treatments in Inflammatory Bowel Disease
Digestive Disease week 2011
Chicago 7-10 mayo 2011
Gastroenterology 2011:140(5) Supp 1,S-271
Pharmacogenetics study of TPMT and ITPA genes in patients with inflammatory bowel disease treated with azathioprine detects relation between ITPase deficiency and clinical response
Digestive Disease week 2011
Chicago 7-10 mayo 2011
Gastroenterology 2011:140(5) Supp 1,S-769.
Premio al mejor póster de su categoría
Pharmacogenetics study of TPMT and ITPA genes in patients with inflammatory bowel disease treated with azathioprine detects relation between ITPase deficiency and clinical response
6th ECCO Congress.
Dublin, Ireland, February 24-26 2011
Journal of Crohn´s & colitis 2011;5(1):s-161
Candidate genes for azathioprine’s efficacy or toxicity in inflammatory bowel disease patients using a exome-wide genotyping analysis
6th ECCO Congress.
Dublin, Ireland, February 24-26 2011
Journal of Crohn´s & colitis 2011;5(1):s-160
Use of adalimumab in anti-TNF naive Crohn’s disease patients: Clinical experience in a multicenter cohort”
6th ECCO Congress.
Dublin, Ireland, February 24-26 2011
Journal of Crohn´s & colitis 2011;5(1):s-106
A Pharmacogenetics study of TPMT and ITPA genes detects relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine
Journal of Gastrointestinal and Liver Diseases. 2011;20:247-53.
Evaluation of adalimumab therapy in multidisciplinarystrategy for perianal Crohn’s disease patients withinfliximab failure
Journal of Crohn’s and Colitis 2010;4(3):654–660.
Clinical practice in Crohn’s disease in bordering regions of two countries:different medical options, distinct surgical events
Journal of Crohn’s and Colitis 2010;4(3):301-311.
Ulcerative colitis in the North of Portugal and Galicia in Spain
Inflammatory Bowel Disease 2010;16:1227-1238.
Long term (5 years) efficacy and safety OFO Infliximab in Crohn disease patients
R. Ferreiro, E. Fernandez-Salgado, V. Ollero, A. Lorenzo Gonzalez, D. Carpio, A. Echarri, A. Fernandez, L. De Castro, J.R. Pineda Marino, V. Hernandez, L. Sanromán, J. Martinez Cadilla, M.A. Pato, E. Santos, S. Pereira, J. Castro, M. Barreiro-de AcostaUEGW Estocolmo
Tratamiento con Adalimumab en enfermos de Chrohn ANTI-TNF NAÏVE. Experiencia gallega
A.Echarri, M.Barreiro, V.Ollero, A.Fernandez, D.Martinez, V.Hernandez, A.Lorenzo, J.Castro, S.Pereira, D.Carpio. H. A. Marcide. Ferrol, H.Clínico.Santiago,H.Povisa.Vigo, CHUVI. Vigo,CH.Pontevedra
Semana de las Enfermedades Digestivas SED 19-22 Junio de 2010 Santiago de Compostela.
A Pharmacogenetics Study of TPMT and ITPA Genes Detects a Relationship with Side Effects and Clinical Response in Patients with Inflammatory Bowel Disease Receiving Azathioprine
William Zabala-Fernández, Manuel Barreiro-de Acosta, Ana Echarri, Daniel Carpio, Aurelio Lorenzo, Javier Castro, David Martínez-Ares, Santos Pereira, Ignacio Martin-Granizo, Marta Corton, Angel Carracedo, Francisco Barros
UEGW / WCOG, London 21-25 Noviembre de 2009
Influence of rural/urban environment severity of Inflammatory Bowel Disease
Barreiro M, Echarri A, Pereira S, Carpio D, Castro J, Ferreiro R, Alvarez V, Lorenzo A.
Digestive Disease Week and the 109th Annual Meeting of the AGA Institute.
San Diego 17-22 may 2008.
Gastroenterology 2008; 134 (4) A-504
Enfermedad de CROHN. ¿Qué ha cambiado en los últimos 10 años?
Barreiro-de Acosta M, Bouzas Sierra R, Cadilla J.M, Carpio López D, Castro Alvariño J, Echarri Piudo A, Fernández Villaverde A, Ghanimé Saide J, López Roses L, Lorenzo González A, Martínez Ares D, Panés Díaz J, Pereira Bueno S.
ISBN 978-84-613-6254-7